M. Angelescu*
* Prof. dr. M. Angelescu, Clinica de Boli Infecţioase Colentina, U.M.F. “Carol Davila”, Bucureşti
Abstract
ln vitro studies have shown it to be more active than cephalexin, the other orally administered cephalosporins in common usage, against many Enterobacter. Haemophilus and Proteus strains. One hundred patients were treated with cefatrizine, including 34 with genitourinary tract infections, 56 with respiratory and 10 with soft-tissue infections. Overall, 87% of the patients treated have responded well to therapy, including 9 5% of those with acute streptococcal pharyngitis, 83% of those with pneumonia, 73% of those with cystitis-phylonephritis, and all patients treated for gonococcal urethritis, sinusitis, and sof-t-tissue infections. Only four bacterial isolates were initially resistant to cefatrizine by “in vitro” disk sensitivity. All relapses were with sensitive bacteria. Drug toxicity was seen in 19 patients, requiring discontinuation of antibiotic in four patients.